WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Wednesday, July 6, 2016

EU clears Bial’s new Parkinson’s drug

By Selina McKee

July 6, 2016




Over the next year certain patients with Parkinson's disease could get access to a new treatment option in Europe after regulators green-lighted Bial's Ongentys.
The European Commission has approved the drug as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors in adult patients with the disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
The decision came after regulatory advisors recommended Ongentys' (opicapone) clearance earlier this year, highlighting its ability to decrease off-time (time when patients are severely restricted by their symptoms) and increase on-time without troublesome dyskinesia.
This was evidenced by data from two pivotal Phase III studies, BIPARK-I and BIPARK II, which demonstrated that the drug achieved an absolute reduction in OFF-time of two hours without increasing ON-time with troublesome dyskinesia, while a one-year extension study also showed that this effect was sustained.
"Motor complications in Parkinson's disease remain an unmet medical need for a significant number of patients," noted Professor Joaquim Ferreira, ‎Professor of Neurology and Clinical Pharmacology at the University of Lisbon. "Opicapone is a new treatment option and fulfils the need for a more potent COMT inhibitor, offering an important alternative to the currently available armamentarium for the treatment of motor fluctuations."
"It may become the treatment of choice when levodopa-treated patients need additional help to improve motor symptoms such as wearing off in Parkinson's disease," added Professor Heinz Reichmann, Professor and Chair Department of Neurology and Dean of Medical Faculty at the University of Dresden.
The European Parkinson's disease Association estimates that 1.2 million people have Parkinson's disease in the European Union. Bial said it plans to start launching its new drug across the region in 2016 and 2017.
http://www.pharmatimes.com/news/eu_clears_bials_new_parkinsons_drug_1059623

No comments:

Post a Comment